Dyadic shares surge 19.34% premarket after CRISPR/Cas9 patent partnership with ERS Genomics.
ByAinvest
Tuesday, Dec 2, 2025 4:06 am ET1min read
DYAI--
Dyadic International Inc. surged 19.34% in premarket trading following two strategic developments: a licensing agreement for CRISPR/Cas9 technology from ERS Genomics and a partnership with Brig Bio to develop and commercialize biologics. The CRISPR deal enhances Dyadic’s genetic engineering capabilities, positioning it to improve bioproduction efficiency and scalability, while the Brig Bio collaboration secures funding for development milestones, validating its platform’s commercial potential. Both partnerships signal long-term growth opportunities in biotechnology, aligning with investor optimism despite mixed third-quarter earnings. The premarket rally reflects market anticipation of these strategic pivots, which could drive future revenue and industry relevance.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet